BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38118405)

  • 1. Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers.
    Savary C; Luciana L; Huchedé P; Tourbez A; Coquet C; Broustal M; Lopez Gonzalez A; Deligne C; Diot T; Naret O; Costa M; Meynard N; Barbet V; Müller K; Tonon L; Gadot N; Degletagne C; Attignon V; Léon S; Vanbelle C; Bomane A; Rochet I; Mournetas V; Oliveira L; Rinaudo P; Bergeron C; Dutour A; Cordier-Bussat M; Roch A; Brandenberg N; El Zein S; Watson S; Orbach D; Delattre O; Dijoud F; Corradini N; Picard C; Maucort-Boulch D; Le Grand M; Pasquier E; Blay JY; Castets M; Broutier L
    Cell Rep Med; 2023 Dec; 4(12):101339. PubMed ID: 38118405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
    Meister MT; Groot Koerkamp MJA; de Souza T; Breunis WB; Frazer-Mendelewska E; Brok M; DeMartino J; Manders F; Calandrini C; Kerstens HHD; Janse A; Dolman MEM; Eising S; Langenberg KPS; van Tuil M; Knops RRG; van Scheltinga ST; Hiemcke-Jiwa LS; Flucke U; Merks JHM; van Noesel MM; Tops BBJ; Hehir-Kwa JY; Kemmeren P; Molenaar JJ; van de Wetering M; van Boxtel R; Drost J; Holstege FCP
    EMBO Mol Med; 2022 Oct; 14(10):e16001. PubMed ID: 35916583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
    Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
    Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
    Patel AG; Chen X; Huang X; Clay MR; Komorova N; Krasin MJ; Pappo A; Tillman H; Orr BA; McEvoy J; Gordon B; Blankenship K; Reilly C; Zhou X; Norrie JL; Karlstrom A; Yu J; Wodarz D; Stewart E; Dyer MA
    Dev Cell; 2022 May; 57(10):1226-1240.e8. PubMed ID: 35483358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
    Manzella G; Moonamale DC; Römmele M; Bode P; Wachtel M; Schäfer BW
    Neoplasia; 2021 Sep; 23(9):929-938. PubMed ID: 34329950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engaging Cell Death Pathways for the Treatment of Rhabdomyosarcoma.
    Dobson CC; Langlois S; Grynspan D; Cowan KN; Holcik M
    Crit Rev Oncog; 2016; 21(3-4):221-239. PubMed ID: 27915973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.
    Kahen E; Yu D; Harrison DJ; Clark J; Hingorani P; Cubitt CL; Reed DR
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):313-23. PubMed ID: 27324022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
    Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
    Ferrari A; Orbach D; Casanova M; van Noesel MM; Berlanga P; Brennan B; Corradini N; Schoot RA; Ramirez-Villar GL; Hjalgrim LL; Alaggio R; Guillen Burrieza G; Safwat A; Cameron AL; van Rijn RR; Minard-Colin V; Zanetti I; Bisogno G; Chisholm JC; Merks JHM
    Cancer; 2023 Aug; 129(16):2542-2552. PubMed ID: 37084075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for pediatric soft-tissue sarcomas.
    Casanova M; Ferrari A
    Expert Opin Pharmacother; 2011 Mar; 12(4):517-31. PubMed ID: 21306288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
    Vaarwerk B; Mallebranche C; Affinita MC; van der Lee JH; Ferrari A; Chisholm JC; Defachelles AS; De Salvo GL; Corradini N; Minard-Colin V; Morosi C; Brisse HJ; McHugh K; Bisogno G; van Rijn RR; Orbach D; Merks JHM
    Cancer; 2020 Feb; 126(4):823-831. PubMed ID: 31750944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.